Showing 4241-4250 of 8129 results for "".
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar
- Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapyhttps://practicaldermatology.com/news/study-gene-expression-test-ids-best-patients-for-adjuvant-radiation-therapy/2462130/New research suggests that a 40-gene expression profile (40-GEP) test can help identify the best patients for adjuvant radiation therapy for cutaneous squamous cell carcinoma (cSCC). The study, whose results were presented at ASDS 2023, consisted of two merged validation cohorts f
- Healiva, C4U Join Forces to Develop New Gene Therapy for EBhttps://practicaldermatology.com/news/healiva-c4u-join-forces-to-develop-new-gene-therapy-for-eb/2462106/Healiva SA (Healiva) and C4U Corporation (C4U) have entered into a strategic alliance agreement regarding the development of CRISPR-Cas3 derived therapeutic solutions for Epidermolysis Bullosa (EB), also known as “butterfly children”. “The collaboration aims to provide
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- Tralokinumab Shows Improvements in Dupilumab Patients Up to 52 Weekshttps://practicaldermatology.com/news/tralokinumab-shows-improvements-in-dupilumab-patients-up-to-52-weeks/2462103/The results of a phase 3 trial expands on the efficacy and safety profile of tralokinumab, the first monoclonal antibody (mAb) that targets IL4Rα, blocking signaling of interleukin (IL)-13 and IL-4. Approved in the EU
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and
- Study: Dupilumab Shows Acceptable Long-term Safety Profile for ADhttps://practicaldermatology.com/news/study-dupilumab-shows-acceptable-safety-profile/2462097/Results from a five-year analysis suggested that long-term dupilumab for the treatment of moderate-to-severe atopic dermatitis (AD) in adults is safe and consistent with other placebo-controlled trials.
- New Insights on the Genetic Link Between Skin Tone and Ancestral Originhttps://practicaldermatology.com/news/new-insights-on-the-genetic-link-between-skin-tone-and-ancestral-origin/2462096/The link between skin pigmentation and ethnicity is more complicated than previously believed, according to new research published in the journal eLife. The team has confirmed that genes associated with East Asian and Native American anc
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- ESMO News: Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%https://practicaldermatology.com/news/esmo-news-major-pathologic-response-to-neoadjuvant-pembrolizumab-in-advanced-melanoma-trial-exceeds-50/2462089/In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other re